KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Amortization of Deferred Charges: 2018-2020

Historic Amortization of Deferred Charges for Castle Biosciences (CSTL) over the last 3 years, with Dec 2020 value amounting to $839,000.

  • Castle Biosciences' Amortization of Deferred Charges fell 26.07% to $173,000 in Q4 2020 from the same period last year, while for Dec 2020 it was $839,000, marking a year-over-year decrease of 56.42%. This contributed to the annual value of $839,000 for FY2020, which is 56.42% down from last year.
  • Latest data reveals that Castle Biosciences reported Amortization of Deferred Charges of $839,000 as of FY2020, which was down 56.42% from $1.9 million recorded in FY2019.
  • Castle Biosciences' 5-year Amortization of Deferred Charges high stood at $1.9 million for FY2019, and its period low was $566,000 during FY2018.
  • For the 3-year period, Castle Biosciences' Amortization of Deferred Charges averaged around $1.1 million, with its median value being $839,000 (2020).
  • Per our database at Business Quant, Castle Biosciences' Amortization of Deferred Charges soared by 240.11% in 2019 and then tumbled by 56.42% in 2020.
  • Over the past 3 years, Castle Biosciences' Amortization of Deferred Charges (Yearly) stood at $566,000 in 2018, then soared by 240.11% to $1.9 million in 2019, then slumped by 56.42% to $839,000 in 2020.